LGALS9 and acute myeloid leukemia: We treated human-derived MOLM-13 cells with different FLT3 inhibitors (crenolanib, quinzartinib, and t andutinib) to prevent FLT3 signaling and observed a decreased expression of Gal-9, CEACAM1, and TIM-3 in FLT3-ITD mutant AML cells, but not in Kasumi-1 cells (FLT3 WT) (Figure 7, F–I), indicating that oncogenic FLT3-ITD signaling upregulates TIM-3 and its ligands in human AML.